-
More
-
Atezolizumab (MPDL3280A), a monoclonal antibody that binds to PD-L1 and blocks its interaction with PD-1, was approved for the treatment of platinum-resistant metastatic non-small cell lung cancer (NSCLC) and cisplatin-resistant bladder cancer.
More
-
Avelumab, a human IgG1 anti–PD-L1 monoclonal antibody, has demonstrated clinical activity with a range of human cancers and has been approved for the treatment of Merkel cell and bladder carcinoma.
More
-
Basiliximab is a monoclonal antibody that binds to the α-chain of the interleukin (IL)-2 receptor and used as induction therapy in kidney transplantation.
More
-
Belimumab (LymphoStat B), a fully humanised mAb against B lymphocyte stimulator (B-LyS), is the first drug to be approved specifically for the treatment of SLE.
More
